Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

Aug 14, 2019

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

Aug 12, 2019

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

Aug 7, 2019

Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Jul 9, 2019

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Jun 3, 2019

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

May 20, 2019

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

May 15, 2019

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

May 6, 2019

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

Apr 18, 2019

Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

Apr 2, 2019